Volume 145, Issue 2, Pages 361-365 (May 2017) Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer Maria Lee, Eun Jae Kim, Youngnam Cho, Sunshin Kim, Hyun Hoon Chung, Noh Hyun Park, Yong-Sang Song Gynecologic Oncology Volume 145, Issue 2, Pages 361-365 (May 2017) DOI: 10.1016/j.ygyno.2017.02.042 Copyright © 2017 The Authors Terms and Conditions
Fig. 1 Immunohistochemistry of captured and subcultured CTCs. A) Up: Immunocytochemistry of single CTCs recovered from peripheral blood, as seen by confocal microscopy (green, EpCAM; blue, DAPI; red, CD45; purple, vimentin) and bottom: Immunocytochemistry of clustered CTCs recovered from peripheral blood, as seen by confocal microscopy (green, EpCAM; blue, DAPI); and B) cultured CTCs resembling originally captured parent cells (20× magnification, all panels). Gynecologic Oncology 2017 145, 361-365DOI: (10.1016/j.ygyno.2017.02.042) Copyright © 2017 The Authors Terms and Conditions
Fig. 2 Responsiveness of captured and subcultured CTCs to chemotherapeutic agents. A, B) CTC cell lines (P10, P14) showing greater sensitivity to cisplatin and paclitaxel than do SKOV3 or OVCAR3 cells; and C) more rapid proliferation of isolated CTCs, relative to SKOV3 or OVCAR3 cells. Gynecologic Oncology 2017 145, 361-365DOI: (10.1016/j.ygyno.2017.02.042) Copyright © 2017 The Authors Terms and Conditions
Supplementary Fig. 1 Kaplan-Meier curves showing progression-free survival (A) and overall survival (B) of newly diagnosed patients according to CTC count (CTCs ≥3 vs. <3). Kaplan-Meier plots demonstrated that patients had CTCs ≥3 had significantly worse progression-free survival (P=0.013). Gynecologic Oncology 2017 145, 361-365DOI: (10.1016/j.ygyno.2017.02.042) Copyright © 2017 The Authors Terms and Conditions
Supplementary Fig. 2 Kaplan-Meier curves showing progression-free survival (A) and overall survival (B) of patients with recurrences according to CTC count (CTCs ≥3 vs. <3). CTC count had no statistical significance on PFS and OS (P=0.334 and P=0.190, respectively). Gynecologic Oncology 2017 145, 361-365DOI: (10.1016/j.ygyno.2017.02.042) Copyright © 2017 The Authors Terms and Conditions